Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 May 1;53(5):afae106.
doi: 10.1093/ageing/afae106.

Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study

Carlen Reyes  1   2 , Danielle Newby  3 , Berta Raventós  1   4 , Katia Verhamme  5 , Mees Mosseveld  5 , Daniel Prieto-Alhambra  3   5 , Edward Burn  3 , Talita Duarte-Salles  1   5
Affiliations
Multicenter Study

Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study

Carlen Reyes et al. Age Ageing. .

Abstract

Background: An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data.

Setting: Primary care data (country/database) from the UK/CPRD-GOLD (2007-20), Spain/SIDIAP (2010-20) and the Netherlands/IPCI (2008-20), standardised to a common data model.

Methods: Cohort study. Participants: dementia patients ≥40 years old with ≥1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)).

Results: We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI.In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891-32,862)) to 2010 (17,793 (17,083-18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021-25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199-52,855)) to 2020 (14,571 (14,109-15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967-29,031)) to 2020 (4763 (4176-5409)). Subjects aged ≥65-79 years and men (in the UK and the Netherlands) initiated more frequently an ADD.

Conclusions: Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.

Keywords: cohort studies; dementia; drug utilization studies; older people.

PubMed Disclaimer

Conflict of interest statement

KV and MM workfor a research group who, in the past 3 years, received unconditional research grants from Chiesi, UCB, Amgen, J&J and the EMA, none of which relate to the content of this work. EB, DN, BR, TDS and CR do not have any conflict of interest. DPA’s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA’s department.

Figures

Figure 1
Figure 1
Overall and individual ADD prescriptions incidence rate per 100,000 person-years: (A) Clinical Practice Research Datalink (CPRD-GOLD), (B) Information System for Research in Primary Care (SIDIAP) and (C) Integrated Primary Care Information (IPCI).
Figure 2
Figure 2
Incidence rate per 100,000 persons-year of ADD prescriptions per age and sex in the Clinical Practice Research Datalink (CPRD-GOLD).
Figure 3
Figure 3
Incidence rate per 100,000 persons-year of ADD prescriptions per age and sex in the Information System for Research in Primary Care (SIDIAP).
Figure 4
Figure 4
Incidence rate per 100,000 persons-year of ADD prescriptions per age and sex in the Integrated Primary Care Information (IPCI).
See this image and copyright information in PMC

References

    1. GBD 2019 Dementia Forecasting Collaborators . Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 2022; 7: e105–25. - PMC - PubMed
    1. Day GS, Scarmeas N, Dubinsky R et al. Aducanumab use in symptomatic Alzheimer disease evidence in focus: a report of the AAN Guidelines Subcommittee. Neurology 2022; 98: 619–31. - PMC - PubMed
    1. van Dyck CH, Swanson CJ, Aisen P et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023; 388: 9–21. - PubMed
    1. Sims JR, Zimmer JA, Evans CD et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023; 330: 512–27. - PMC - PubMed
    1. Miculas DC, Negru PA, Bungau SG, Behl T, Hassan SSU, Tit DM. Pharmacotherapy evolution in Alzheimer's disease: current framework and relevant directions. Cells 2022; 12: 131. - PMC - PubMed

Publication types

Substances